Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

Main Article Content

D Thaçi
A Armstrong
M Lebwohl
A Blauvelt
C Paul
L Puig
M Wang
V Vanvoorden
C Madden
S Wiegratz
D Deherder
KB Gordon


bimekizumab, maintenance, efficacy, psoriasis, phase 3, clinical trial




1. Warren RB et al. N Engl J Med 2021;385:130–141, NCT03412747

2. Reich K et al. Lancet 2021;397:487–498, NCT03370133

3. Gordon KB et al. Lancet 2021;397:475–486, NCT03410992

4. Reich K et al. N Engl J Med 2021;385:142–152, NCT03536884

5. BE BRIGHT: NCT03598790

Most read articles by the same author(s)

1 2 3 4 5 > >>